Activated platelet-derived microparticles in thalassaemia

Kovit Pattanapanyasat1, Siriphan Gonwong, Porntip Chaichompoo

  • 1Centre of Excellence for Flow Cytometry, Office for Research and Development, Department of Immunology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok. grkpy@mahidol.ac.th

Insights

Thrombotic risk in beta-thalassaemia is linked to increased microparticles (MPs) from activated platelets, especially in splenectomised patients. These MPs contribute to clotting, highlighting a key factor in disease complications.

Area of Science:

  • Hematology
  • Thrombosis Research
  • Cell Biology

Background:

  • Thalassaemia patients exhibit increased thromboembolic complications.
  • Abnormal red blood cell aggregability and elevated microparticles (MPs) are implicated in thrombotic risk.

Purpose of the Study:

  • To investigate the quantity, cellular origin, and procoagulant properties of MPs in beta-thalassaemia.
  • To understand the role of MPs in the thrombotic risk associated with beta-thalassaemia.

Main Methods:

  • Flow cytometry was used to analyze MPs in fresh whole blood from beta-thalassaemia/HbE patients (splenectomised and non-splenectomised) and normal individuals.
  • Blood samples were stained for annexin V, cellular antigens (CD41a, CD62P, CD36), and density beads.
  • Platelet factor-3-like activity was measured to assess procoagulant properties of phosphatidylserine (PS)-bearing MPs.

Main Results:

  • Splenectomised beta-thalassaemia/HbE patients showed significantly higher levels of PS-bearing MPs compared to non-splenectomised patients and controls (P < 0.0001).
  • A strong correlation was found between PS-bearing MPs and PS-bearing platelets, indicating chronic platelet activation (r(s) = 0.511, P < 0.001).
  • PS-bearing MPs primarily originated from activated platelets, and platelet procoagulant activity was elevated in splenectomised patients, correlating with MP levels.

Conclusions:

  • Microparticles in beta-thalassaemia, particularly from activated platelets, contribute to thrombotic risk.
  • Elevated levels of these procoagulant MPs, especially in splenectomised patients, can aggravate thrombotic events.